Joseph Wagner
About Joseph Wagner
Joseph Wagner, PhD, is the Chief Scientific Officer at Notable Labs, where he has significantly advanced the Predictive Precision Medicines Platform (PPMP) and contributed to the development of therapeutic candidates for acute myeloid leukemia.
Joseph Wagner Chief Scientific Officer
Joseph Wagner serves as the Chief Scientific Officer at Notable Labs. In this role, he is responsible for overseeing the scientific research and development efforts within the company. Wagner has played a key role in advancing Notable Labs' strategic initiatives, particularly in the application and utilization of the Predictive Precision Medicines Platform (PPMP). His leadership has been critical to the company's efforts to push forward innovative treatments in the realm of precision medicine.
Joseph Wagner Education and Expertise
Joseph Wagner holds a PhD and has specialized expertise in the field of precision medicine. His academic background and research experiences enable him to contribute significantly to the scientific and medical community. Wagner's expertise is reflected in his pivotal role in the development and application of the Predictive Precision Medicines Platform (PPMP) at Notable Labs. This platform aims to enhance the precision and efficacy of therapeutic developments.
Joseph Wagner Contributions to Predictive Precision Medicines Platform (PPMP)
Joseph Wagner has made notable contributions to the Predictive Precision Medicines Platform (PPMP) at Notable Labs. His work with PPMP has been instrumental in advancing the selection and development of two clinical-stage therapeutic candidates. Additionally, his efforts include leveraging extensive post-hoc analyses from original Phase 2 and 3 trials to enhance patient response and tolerability in the Volasertib Phase 2 trial. His strategic approach focuses on reducing risk, time, and cost in drug development.
Joseph Wagner and Volasertib Development for AML
Joseph Wagner has been significantly involved in the development of Volasertib, a therapeutic candidate for the treatment of acute myeloid leukemia (AML). As part of his efforts, Wagner enriched the Phase 2 program of Volasertib using the Predictive Precision Medicines Platform (PPMP), aiming to identify and enroll patients who are more likely to respond clinically. His contributions have been pivotal in accelerating the development pipeline for this promising treatment.
Joseph Wagner Role in Notable Labs and VBL Therapeutics Merger
Joseph Wagner played an integral role in the merger transaction between Notable Labs and VBL Therapeutics. This strategic move was aimed at accelerating the development and commercialization of Volasertib for the treatment of AML. Wagner's involvement underscored his commitment to advancing therapeutic options and leveraging corporate synergies to enhance clinical outcomes and expedite drug development processes.